Back to results
US 10,064,934 B2Granted
Combination PIV3/hMPV RNA vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Sunny Himansu
Life of this patent
Estimating the term…
Abstract
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims25
A respiratory virus vaccine comprising:
- (a) an isolated messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding an antigenic human parainfluenza virus type 3 (hPIV3) Fusion (F) protein;
- and
- (b) an isolated mRNA polynucleotide comprising an open reading frame encoding an antigenic human metapneumovirus (hMPV) F protein,
- formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine,
- wherein the isolated mRNA polynucleotide of (a) and the isolated mRNA polynucleotide of (b) are not self-replicating RNA.
2 more elements
Dependencies are inferred from the claim text.